利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.017 秒)

    HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION
    4.
    发明申请
    HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION 审中-公开
    杂环化合物治疗肺炎衣原体感染

    公开(公告)号：WO2018013430A2

    公开(公告)日：2018-01-18

    申请号：PCT/US2017/041218

    申请日：2017-07-07

    申请人： ARISAN THERAPEUTICS INC.

    发明人： PLEWE, Michael ,  BROWN, Eric ,  GANTLA, Vidyasagar ,  HENKEL, Gregory ,  MCCORMACK, Kenneth ,  SOKOLOVA, Nadzeda V. ,  SHIN, Young-Jun

    IPC分类号： A61K31/4745 ,  A61K31/4184

    摘要： The invention relates to compounds of structural formula I, wherein A, D, and E are independently N or C-R 3 , G, H, and J are independently N or C, K is N or C-H, L is N, N-R 3 or C-R 3 , and A, D, E, G, H, J, K, and L together cannot have more than 4 N, R 1 is selected from (C 6 to C 10 ) aryl, (C 2 to C 9 ) heteroaryl, and 5-indolyl, wherein each of the said (C 6 to C 10 ) aryl and (C 2 to C 9 ) heteroaryl is substituted with at least one R 4a group, and wherein said (C 2 to C 9 ) heteroaryl is C-attached, and R 2 is selected from the group consisting of (i), (ii), (iii), and (iv).

    摘要翻译： 本发明涉及结构式I的化合物，其中A，D和E独立地为N或CR 3，G，H和J独立地为N或C ，K是N或CH，L是N，NR 3或CR 3，并且A，D，E，G，H，J，K和L一起不能 具有多于4个N，R 1选自（C 6至C 10）芳基，（C 2 其中每个所述（C 6至C 10）芳基和（C 6至C 10）芳基各自独立地选自氢， 2至C 9）杂芳基被至少一个R 4a基团取代，并且其中所述（C 2至C 4） （i），（ii），（iii）和（iv）组成的组中，R 2是C连接的，且R 2选自（i），（ii），（iii）和（iv）。

    HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS
    5.
    发明申请
    HETEROCYCLIC COMPOUNDS AS THERAPEUTIC AGENTS 审中-公开

    公开(公告)号：WO2022108849A1

    公开(公告)日：2022-05-27

    申请号：PCT/US2021/059268

    申请日：2021-11-12

    申请人： ARISAN THERAPEUTICS INC.

    发明人： SOKOLOVA, Nadezda ,  MCCORMACK, Kenneth ,  HENKEL, Gregory ,  GANTLA, Vidyasagar Reddy ,  BROWN, Eric

    IPC分类号： A01N43/90 ,  A01N47/40 ,  C07D471/04

    摘要： The invention relates to compounds of structural formula I wherein A is independently N or C-R3, R1 is selected from (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) heterocycloalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl, wherein each of the said (C1 to C6) alkyl, (C2 to C6) alkenyl, (C2 to C6) alkynyl, (C3 to C10) cycloalkyl, (C5 to C10) cycloalkenyl, (C2 to C9) heterocycloalkyl, (C6 to C10) aryl, and (C2 to C9) heteroaryl is optionally substituted with at least one R4 group, and wherein said (C2 to C9) heteroaryl is C-attached, and R2 is selected from the group consisting of Formula (II), Formula (III), Formula (IV), Formula (V) and formula (VI)..